James A. Joyce
Co-Founder, Chairman, CEO, Inventor & Interim CFOMr. James A. Joyce, also known as Jim, Ph.D. is Co-Founder, Chairman and Chief Executive Officer of Sigyn Therapeutics, Inc. from 2019 and also serves as its Interim CFO since February 26, 2025 and served as its Chief Financial Officer. He founded Aethlon Medical Inc. (formerly Bishop Equities Inc.) in May 1998 and was its Secretary. He served as Chief Executive Officer at Aethlon Medical Inc. from June 01, 2001 to December 10, 2018. He diverse public market experience, which includes two decades of public company Chief Executive Officer and Corporate Board leadership roles. In the field of medical technology, Mr. Joyce has founded and led organizations that have achieved several first-in-industry milestones. He is also the Founder and former Executive Chairman of Exosome Sciences, Inc from 2011 to December 1, 2018. Mr. Joyce serves as the President at Exosome Sciences, Inc. He served as the Chief Financial Officer of Aethlon Medical Inc. until September 2010. He served as the President of Aethlon Medical Inc. from June 1, 2001 to October 27, 2010. At Aethlon, he served as President from June 1, 2001 to July 18, 2006 and also served as its Co-President. He served as the Principal Accounting Officer of Aethlon Medical, Inc. since December 31, 2007. He has led the efforts that have resulted in the recent acquisitions of Hemex Inc., Syngen Research Inc. and Cell Activation Inc. In February 1993, he founded and served as the Chief Executive Officer of James Joyce & Associates. From 1989 to 1991, he served as Chairman of the Board and Chief Executive Officer of Mission Labs Inc. and a Principal in charge of U.S. operations for London Zurich Securities Inc. He is a Director of Reign Resources Corporation. He served as Chairman of Aethlon Medical, Inc. since March 1999 until November 29, 2017 until March 10, 1999. During his tenure at Aethlon, Mr. Joyce oversaw the development of the Hemopurifier, a first-in-class blood purification technology to address life-threatening viruses and cancer-promoting exosomes. Under Mr. Joyce’s leadership, the Hemopurifier® became the first therapeutic candidate to be awarded two FDA “Breakthrough Device” designations and is the first and only device to receive “Emergency Use Authorization” (EAU) approval from both the FDA and Health Canada to treat Ebola virus. While employed at Aethlon from 1999 to 2018, Mr. Joyce oversaw the development of the Aethlon Hemopurifier, the first therapeutic candidate to receive two “Breakthrough Device” designations from the FDA. Under his leadership, the Hemopurifier received FDA “Emergency Use Authorization” (EAU) approval to treat Ebola virus and additionally was cleared to treat Ebola by the German Government and Health Canada. rior to the EAU award, the Hemopurifier® was cleared to treat Ebola in Germany. Additionally, the Hemopurifier® was the recipient of an FDA approved “Investigational Device Exemption” to support clinical programs to treat a broad-spectrum of life-threatening viruses that are not addressed with antiviral drugs. Time Magazine named the Hemopurifier® one of the “11 Most Remarkable Advances in Healthcare” and designated the device to its “Top 25 Best Inventions” award list. Readers Digest Magazine placed the Hemopurifier® on its “Top 10 Medical Breakthroughs” award list. He served as Director at Aethlon Medical Inc. since March 10, 1999 until December 2018. He is a graduate from the University of Maryland in 1984.
Positions
- Company NameSigyn Therapeutics, Inc.Stock CodeSIGYPositionCo-Founder, Chairman, CEO, Inventor & Interim CFO
